Our data showed that miR-152 sensitized breast cancer cells to paclitaxel treatment by targeting β-catenin and PKM2 repression, suggesting a novel role of miR-152 in breast cancer paclitaxel resistance. This evidence concerns the gene PKM and breast carcinoma.